Primary HIV infection: To treat or not to treat?

Current Opinion in Infectious Diseases

Volumn 21, Issue 1, 2008, Pages 4-10

  Fidler, Sarah ^a   Fox, Julie ^a   Porter, Kholoud ^b   Weber, Jonathan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Antiretroviral therapy (ART); Primary HIV infection; Seroconverters

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38149139520     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f428bf     Document Type: Review

References (78)

1. May M, Sterne JA, Sabin C, et al., Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
2. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. The SMART trial was a large international study designed to examine the effects of intermittent treatment in HIV-positive patients. The study found that CD4 guided treatment interruptions were associated with an increased risk of disease progression, AIDS and death.
3. The STEP study (HVTN 502, Merck V520 Protocol 023) vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate. http://www.merck.com/newsroom/press_releases/ research_and_development/2007_0921.html. [Accessed 1 October 2007].
4. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-98.
5. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
6. Keet IPM, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7:51-57.
7. Sinicco A, Fora R, Sciandra M, et al. Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993; 6:575-581.
8. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200x10(sup 6)/l, AIDS and death from AIDS? BMJ 1994; 309:1535-1537.
9. Veugelers PJ, Kaldor JM, Strathdee SA, et al. Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis 1997; 176:112-117.
10. Boufassa F, Bachmeyer C, Carre N, et al. Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis 1995; 171:1190-1195.
11. Goujard C, Bonarek M, Meyer L, et al. Agence Nationale de Recherche sur le Sida. PRIMO Study Group 2006 CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-715.
12. Rouzioux C, Hubert JB, Burgard M, SEROCO Cohort Study Group. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46-55.
13. Brenchley JM, Schaker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 6:749-759.
14. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15:114-117.
15. Derdeyn CA, Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol 2005; 17:366-373.
16. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12:289-295.
17. Brenchley JM, Ruff LE, Casazza JP, et al. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 2006; 80:6801-6809.
18. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 2007; 4:42-47.
19. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007; 81:8838-8842.
20. Silvestri G, Sodora D, Koup R, et al. Non pathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18:441-452.
21. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007; 81:8838-8842.
22. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371. This study showed that circulating lipopolysaccharide, an indicator of microbial translocation, correlates with HIV-related systemic immune activation in humans and simian immunodeficiency virus in rhesus macaques (P=0.002).
23. Guadelupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastro-intestinal mucosa of human immunodeficiency virus type-1 infected patients initiating therapy during primary or chronic infection. J Virol 2006; 16:8236-8247.
24. Vasan S, Poles MA, Horowitz A, et al. Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol 2007; 19:943-951.
25. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLosMedicine 2006; 3:12-18.
26. Centlivre M, Sala M, Wain-hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1-11.
27. Kinloch-De Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333:408-413.
28. Smith D, Walker B, Cooper D, et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18:709-718.
29. Jansen CA, De Cuyper IM, Steingrover R, et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS 2005; 19:1145-1154.
30. Hecht F, Wang L, Collier A, et al., AIEDRP network. A multicentre observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733.
31. Fidler S, Fox J, Touloumi G, et al. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS 2007; 21:1283-1291.
32. Lampe FC, Porter K, Kaldor J, et al., CASCADE Collaboration. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the quest trial results with CASCADE natural history study. Antivir Ther 2007; 12:189-193.
33. Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194:734-739.
34. Fidler S, Fraser C, Fox J, et al. Comparative potency of three antiretroviral therapy regimes in primary HIV infection. AIDS 2006; 20:247-252.
35. Fidler S, Frater J, Clarke J, Weber J. HIV-1 drug resistance in primary infections in the UK. BMJ 2001; 323:632-633.
36. SPARTAC DSMB report 2007 Jan. http://www.ctu.mrc.ac.uk/studies/spartac. asp. [Accessed 22 September 2007].
37. Short Pulse Anti-Retroviral Treatment at Seroconversion (SPARTAC). MRC 2006. http://www.ctu.mrc.ac.uk/studies/spartac.asp. [Accessed 22 November 2007]
38. ACTG A5217. A 96-week randomized, open-label study of the effects on the virologic setpoint of 36 weeks of potent antiretroviral therapy administered during early but not acute HIV-1 infection. http://www.aiedrp.org/studies.asp. [Accessed 1 October 2007]
39. Taylor S, Allen S, Smit E, et al. The Stop Study: after discontinuation of efavirenz (EFV), plasma concentrations can persist for >2 weeks [abstract]. HIV Medicine 2004; 5 (Suppl 2):3.
40. Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis 2005; 192:545-546.
41. Fox JM, Fidler S, Weber J. Resistance to HIV drugs in UK may be lower in some areas. BMJ 2006; 332:179-180.
42. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003l 2:624-634.
43. Skiest DJ, Su Z, Havlir DV, et al., AIDS Clinical Trials Group 5170 Study Team. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436.
44. Phillips A, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART [abstract]. In: Fourteenth Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 41.
45. Hunt PW, Deeks SG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis 2006; 194:1632-1634. This review describes the pathogenesis of acute and chronic HIV infection.
46. Kaufman DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 2:e41.
47. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
48. Younes SA, Trautmann L, Yassine-Diab B, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol 2007; 178:788-797.
49. Kinloch de Loes S, Hoen B, Smith DE, et al., Quest Study Group. Impact of therapeutic immunisation on HIV-1 viraemia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617.
50. Markowitz M, Perelson AS. HIV-1 viral dynamics studies in the setting of clinical trials: a window of opportunity. J Infect Dis 2007; 195:1087-1088.
51. Hazenberg MD,Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
52. Resino S, Seoane E, Gutierrez MD, et al. CD4+ T-cell immunodeficiency is more dependent on immune activation than viral load in HIV infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 42:269-276.
53. Deeks SG, Kitchen CM, Lui L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942-947.
54. Argyropoulos C, Mouzaki A. Immunosuppressive drugs in HIV disease. Curr Top Med Chem 2006; 6:1769-1789.
55. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-688.
56. López M, Benito JM, Lozano S, et al. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. AIDS 2004; 18:1251-1261.
57. Gilliam BL, Heredia A, Devico A, et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007; 21:2108-2110.
58. Center for HIV-AIDS Vaccine Immunology. http://www.chavi.org/. [Accessed 17 September 2007]
59. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
60. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-958.
61. Pao D, Fisher M, Hue S, et al. transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85-90.
62. Pilcher CD, Tien HC, Eron J Jr, et al. Brief but efficient: acute infection and the sexual transmission of HIV Quest study and Duke UNC Emory Acute HIV consortium. J Infect Dis 2004; 189:1785-1792.
63. Pilcher CD, Joaki G, Hoffman IF, et al., for the UNC Project, Malawi. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730.
64. Hayes RJ, White RG. Amplified HIV transmission during early stage infection (letter and reply). J Infect Dis 2006; 193:604-606.
65. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:249-258.
66. Gisselquist D, Potterat JJ. Questioning Wawer, et al.'s estimated rate of sexual HIV transmission from persons with early HIV infections. J Infect Dis 2005; 192:1497-1499; author reply 1499-1500.
67. Montaner JAS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536. This article reviews the role of extending treatment to those with higher CD4 cell counts, for benefit of individual and community. It argues that such an extension can now be contemplated in light of recent improvements in drug formulations (thus enhancing adherence) and reductions in HAART toxicities.
68. Pillay D, Fisher M. Primary HIV infection, phylogenetics and antiretroviral prevention. J Infect Dis 2007; 195:924-926.
69. HTNP 052. A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. HIV Prevention TrialsNetwork. http://www.hptn.org/research_studies/hptn052.asp. [Accessed 22 November 2007]
70. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy; 2006. http://www.bhiva.org. [Accessed 12 September 2007]
71. Treatment for Adult HIV Infection. Recommendations of an International AIDS Society-USA Panel. JAMA 2006; 296:827-843.
72. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
73. Oxenius A, Price DA, Günthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 2002; 15:13747-13752.
74. Seng R, Goujard C, Desquilbet L, et al. CD4 T cell count increase during HAART initiated in primary infection is transient after long-term HAART interruption [abstract]. In: Fourteenth Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 347.
75. Desquilbet L, Goujard C, Rouzioux C, et al., PRIMO and SEROCO Study Groups. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18:2361-2369.
76. Kasutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-873.
77. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700-708.
78. Hoen B, Cooper DA, Lampe FC, et al., The QUEST Study Group. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST EW PROB3005. Clin Infect Dis 2007 45:381-90. [epub Jun 2007]